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ABSTRACT
The proportion of enterococcal infections caused
by ampicillin-resistant Enterococcus faecium
(AREfm) in a European hospital increased from
2% in 1994 to 32% in 2005, with prevalence rates
of AREfm endemicity of up to 35% in at least six
hospital wards. Diabetes mellitus, three or more
admissions in the preceding year, and use of
b-lactams and ﬂuoroquinolones, were all associ-
ated with AREfm colonisation. Of 217 AREfm
isolates that were genotyped, 97% belonged to
clonal complex 17 (CC17). This ecological change
mimics events preceding the emergence of vanco-
mycin-resistant E. faecium (VREF) in the USA and
may presage the emergence of CC17 VREF in
European hospitals.
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Molecular epidemiological studies of Enterococcus
faecium have revealed the existence of host-speci-
ﬁc genogroups, including an ampicillin-resistant
genetic lineage, labelled clonal complex 17
(CC17), which are associated with nosocomial
outbreaks and infections in ﬁve continents [1]. In
European hospitals, rates of infection with vanco-
mycin-resistant E. faecium have been rising since
the year 2000 (EARSS Annual Report 2004;
http://www.rivm.nl/earss), suggesting that the
emergence of vancomycin-resistant E. faecium in
Europe may be following the pattern observed in
the USA, but with a 10-year delay. The emergence
of vancomycin-resistant E. faecium in the USA was
preceded by the emergence of ampicillin resist-
ance in E. faecium [2,3].
Stimulated by an increase in ampicillin-resistant
E. faecium (AREfm) bloodstream infections during
2003, the present study analysed trends in entero-
coccal infection and colonisation at the University
Medical Centre, Utrecht, The Netherlands (1042
beds). The prevalence of invasive enterococcal
infections was assessed retrospectively using
microbiological data for 1994–2005. Invasive infec-
tions were deﬁned as infectious episodes with
enterococci isolated from normally sterile speci-
mens, e.g., blood, abdominal ﬂuid, intravascular
catheter tips, cerebrospinal ﬂuid, pus and wound
specimens. Enterococci isolated from urine were
not considered to represent invasive infections.
Yearly proportions of Enterococcus faecalis and
E. faecium among enterococcal bloodstream infec-
tions were determined on the basis of the ﬁrst 20
enterococcal blood culture isolates (one per
patient) per year. The intestinal AREfm reservoir
was measured by monthly point-prevalence stud-
ies between August 2005 and January 2006 in
seven hospital wards (haematology, 21 beds;
gastroenterology ⁄nephrology, 25 beds; adult
intensive care unit (ICU), 24 beds; paediatric
ICU, 47 beds; geriatrics, 15 beds; general surgery,
30 beds; and dermatology, 12 beds). The AREfm
reservoir in the community was investigated
using faecal samples from 650 outpatients with
abdominal discomfort who visited general practi-
tioners in the Utrecht region during 2004.
Risk-factors for colonisation with AREfm were
determined using clinical and demographical
data for patients in the mixed gastroenterology ⁄
nephrology ward. Statistical analysis was per-
formed with SPSS v.12.0.1 (SPSS Inc., Chicago,
IL, USA). The clinical impact of AREfm was
determined by analysis of clinical, demogra-
phical and outcome data for all patients with
an invasive AREfm infection between May 2001
and November 2005.
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Enterococcosel enrichment broth and agar
plates (Becton Dickinson, Cockeysville, MD,
USA), supplemented with aztreonam 75 mg ⁄L
and amoxycillin 16 mg ⁄L, were used to obtain
isolates of AREfm. Resistance was conﬁrmed by
amoxycillin Etests (AB Biodisk, Solna, Sweden).
A species-speciﬁc multiplex PCR, based on the
ddl gene of E. faecalis and E. faecium, was used
for speciation [4]. Susceptibilities to ampicillin
and imipenem were determined by inoculation
of Mueller–Hinton agar containing ampicillin
8 mg ⁄mL and imipenem 16 mg ⁄mL, according
to CLSI (formerly NCCLS) guidelines. Isolates
were genotyped using multiple locus variable
number tandem repeat analysis (MLVA), which is
based on variations in the number of tandem
repeats at six different loci [5]. MLVA proﬁles
were analysed using BioNumerics v.4.00 (Applied
Maths, St-Martins-Latem, Belgium).
The overall number of patients with invasive
enterococcal infections decreased from 393 in 1994
to 243 in 2005, but proportions of ampicillin-
resistant enterococcal infections increased from
2% in 1994 to 32% in 2005 (p <0.001) (Fig. 1).
E. faecium increased from 3% of enterococcal
bloodstream infections in 1994–1996 to 30% in
2003–2005 (p <0.001), and 75% of E. faecium blood
culture isolates were resistant to both ampicillin
and imipenem, compared with 0% for E. faecalis
(p <0.001).
Point-prevalence studies revealed carriage rates
ranging from 0% in dermatology to 10.3% in the
paediatric ICU, 29% in gastroenterology ⁄neph-
rology, 29.2% in the adult ICU, 34.6% in haema-
tology and 34.8% in geriatrics. AREfm isolates
were obtained from 19 (2.9%) of 650 community-
derived faecal samples. No data were available
concerning previous hospitalisation or antibiotic
use for these patients.
Diabetes mellitus (OR 8.59, 95% CI 2.08–35.44),
three or more admissions in the preceding year
(OR 14.84, 95% CI 3.44–64.10) and use of b-lac-
tams (OR 2.97, 95% CI 1.09–8.09) or quinolones
(OR 5.23, 95% CI 1.22–22.48) were associated
independently with AREfm colonisation
(Table 1).
Between May 2001 and November 2005, 167
patients had an AREfm infection, with blood
(n = 53) and pus (n = 30) as the predominant
samples. Overall, 154 (92%) of 167 patients had
received antibiotics before developing an infection
with AREfm. Nineteen of 20 haematology patients
with AREfm infection had bacteraemia. Haema-
tology patients in the studied hospital receive
ciproﬂoxacin prophylaxis during prolonged
granulocytopenia, and imipenem is the empirical
antibiotic regimen for granulocytopenic fever.
During 2002–2005, 7% (n = 12) of all episodes of
bacteraemia during granulocytopeniawere caused
by AREfm. The average period between obtaining
blood cultures and commencing appropriate anti-
microbial therapy (i.e., vancomycin) was 2 days.
Of 167 patients with invasive AREfm infections, 58
(35%) died during hospitalisation, with an average
period of 15 days (0–105 days) between identiﬁ-
cation of the AREfm infection and death.
MLVA typing of 217 AREfm isolates revealed
40 different MLVA types, of which 211 (97%)
belonged to CC17 (data not shown). A gradual
increase in infection and colonisation episodes
with CC17 E. faecium has occurred in this hospital
in recent years, with bacteraemia accounting for
32% of all infections, an overall mortality rate of
35%, and CC17 infections being most prevalent
among high-risk patients (i.e., transplant or ICU
patients).
E. faecium CC17 consists mainly of clinical
isolates and isolates associated with hospital
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Fig. 1. Invasive enterococcal infec-
tions, 1994–2005. n, No. of patients
with enterococcal bloodstream infec-
tions. r, No. of patients with other
invasive enterococcal infection. n,
Percentage of invasive ampicillin-
resistant (AmpR) enterococci among
the total number of invasive entero-
cocci.
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outbreaks of vancomycin-resistant enterococci
(VRE) [1]. Strains colonising healthy individuals
and animals cluster, almost without exception,
outside this complex. It has been postulated that
speciﬁc adaptations to the hospital environment
that facilitate efﬁcient spread are the reasons for
the success of this pathogen [1]. However, the
spread of multiple CC17 subclones, without an
existing community reservoir, can only be
explained by cross-transmission and selective
antibiotic pressure. Increasing rates of infection
with AREfm present a therapeutic dilemma, as
amoxycillin has been the preferred antibiotic for
invasive enterococcal infections. In bone marrow
transplant patients (for whom imipenem was
ﬁrst-choice therapy for granulocytopenic fever),
surveillance for AREfm carriage has now been
implemented and vancomycin has been added to
imipenem for the treatment of granulocytopenic
fever in AREfm carriers.
A similar rise of AREfm may have preceded the
nationwide nosocomial epidemic of VRE in the
USA. Three longitudinal microbiology-based
studies in the USA reported changes in E. faecal-
is ⁄E. faecium ratios in hospital infections [6–8].
High prevalence and nosocomial spread of
AREfm have also been reported, albeit sporadic-
ally, in European countries [9–14]. The emergence
of AREfm may presage the emergence of VRE,
following horizontal transfer of vancomycin
resistance genes into AREfm [15,16]. In Europe,
the prevalence of VRE carriage among healthy
individuals decreased to 3% after the ban on the
use of avoparcin in the agricultural industry in
1996 [17,18]. However, the prevalence of VRE in a
cohort of non-hospitalised patients in the Utrecht
Table 1. Risk-factor analysis for col-
onisation with ampicillin-resistant
Enterococcus faecium
Variable
Cases (%)
(n = 43)
Controls (%)
(n = 93) OR 95% CI p valuea
Univariate analysis
Demographical and clinical data
Medical specialty (nephrology) 72.1 39.8 3.91 1.78–8.57 <0.001
Age, mean years (±SD) 57.4 (±14.4) 54.4 (±16.0) 0.29b
Male gender 51.2 43.0 1.39 0.67–2.87 0.38
Length of stay, median days (range) 10 (1–78) 7 (1–55) 0.19c
Number of readmissions
in preceding year
0 32.6 59.1 <0.001
1–2 37.2 35.5
‡3 30.2 5.4
CAPD 27.9 9.7 3.613 1.39–9.41 0.006
Haemodialysis 25.6 9.7 3.208 1.22–8.47 0.02
Kidney transplantation 27.9 14 2.382 0.98–5.79 0.05
Recent surgery 34.9 24.7 1.630 0.74–3.57 0.22
Malignancy 4.7 8.7 0.25
Immunocompromised state 50 27.2 2.680 1.25–5.73 0.01
Systemic use of corticosteroids 48.8 29 2.333 1.11–4.93 0.03
Cirrhosis of the liver 9.3 5.4 1.805 0.46–7.09 0.39
Crohn’s disease 2.3 5.4 0.419 0.05–3.7 0.42
Colitis ulcerosa 0 2.2 0.33
Diabetes mellitus 23.3 8.6 3.220 1.17–8.87 0.02
Antibiotic usage 76.7 49.5 3.372 1.49–7.63 0.003
b-Lactams 65.1 37.6 3.09 1.46–6.58 0.004
Co-trimoxazole 25.6 8.6 3.652 1.35–9.9 0.008
Macrolides 4.7 3.2 1.463 0.24–9.1 0.68
Vancomycin 2.3 3.2 0.714 0.07–7.07 0.77
Quinolones 18.6 5.4 4.023 1.23–13.15 0.02
Aminoglycosides 4.7 10.8 0.405 0.09–1.93 0.24
Multivariate analysisd
CAPD 2.75 0.82–9.20 0.10
Haemodialysis 3.44 0.96–12.36 0.06
Kidney transplantation 0.44 0.09–2.24 0.32
Immunocompromised state 1.14 0.22–5.95 0.88
Systemic use of corticosteroids 5.68 1.18–27.31 0.30
Diabetes mellitus 8.59 2.08–35.44 0.003
b-Lactams 2.97 1.09–8.09 0.03
Co-trimoxazole 2.38 0.58–9.71 0.23
Quinolones 5.23 1.22–22.48 0.03
Number of readmissions
in preceding year 0 1 Reference 0.001
1–2 1.75 0.62–4.91 0.29
‡3 14.84 3.44–64.10 <0.001
aChi-square test.
bt-test.
cMann–Whitney test.
dLogistic regression on variables with p <0.100.
CAPD, continuous ambulatory peritoneal dialysis.
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region during the year 2000 was still 2% [19],
which represents a relatively abundant pool of
vancomycin resistance genes in the community.
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